161 related articles for article (PubMed ID: 21618353)
1. Long-term durability of response to adalimumab in Crohn's disease.
Chaparro M; Panés J; García V; Merino O; Nos P; Domènech E; Peñalva M; García-Planella E; Esteve M; Hinojosa J; Andreu M; Muñoz F; Gutiérrez A; Mendoza JL; Barrio J; Barreiro-de M; Vera I; Vilar P; Cabriada JL; Montoro MA; Aldeguer X; Saro C; Gisbert JP
Inflamm Bowel Dis; 2012 Apr; 18(4):685-90. PubMed ID: 21618353
[TBL] [Abstract][Full Text] [Related]
2. Long-term efficacy of adalimumab in paediatric Crohn's disease patients naïve to other anti-TNF therapies.
Martín-de-Carpi J; Pociello N; Varea V
J Crohns Colitis; 2010 Nov; 4(5):594-8. PubMed ID: 21122566
[TBL] [Abstract][Full Text] [Related]
3. Crohn's disease outpatients treated with adalimumab have an earlier secondary loss of response and requirement for dose escalation compared to infliximab: a real life cohort study.
Ma C; Huang V; Fedorak DK; Kroeker KI; Dieleman LA; Halloran BP; Fedorak RN
J Crohns Colitis; 2014 Nov; 8(11):1454-63. PubMed ID: 24947334
[TBL] [Abstract][Full Text] [Related]
4. Clinical experience with infliximab and adalimumab in a single-center cohort of patients with Crohn's disease.
Riis A; Martinsen TC; Waldum HL; Fossmark R
Scand J Gastroenterol; 2012 Jun; 47(6):649-57. PubMed ID: 22472026
[TBL] [Abstract][Full Text] [Related]
5. Mucosal healing at 3 months predicts long-term endoscopic remission in anti-TNF-treated luminal Crohn's disease.
af Björkesten CG; Nieminen U; Sipponen T; Turunen U; Arkkila P; Färkkilä M
Scand J Gastroenterol; 2013 May; 48(5):543-51. PubMed ID: 23477356
[TBL] [Abstract][Full Text] [Related]
6. Infliximab vs. adalimumab in Crohn's disease: results from 327 patients in an Australian and New Zealand observational cohort study.
Doecke JD; Hartnell F; Bampton P; Bell S; Mahy G; Grover Z; Lewindon P; Jones LV; Sewell K; Krishnaprasad K; Prosser R; Marr D; Fischer J; R Thomas G; Tehan JV; Ding NS; Cooke SE; Moss K; Sechi A; De Cruz P; Grafton R; Connor SJ; Lawrance IC; Gearry RB; Andrews JM; Radford-Smith GL;
Aliment Pharmacol Ther; 2017 Feb; 45(4):542-552. PubMed ID: 27995633
[TBL] [Abstract][Full Text] [Related]
7. Long-term MRI-guided combined anti-TNF-α and thiopurine therapy for Crohn's perianal fistulas.
Tozer P; Ng SC; Siddiqui MR; Plamondon S; Burling D; Gupta A; Swatton A; Tripoli S; Vaizey CJ; Kamm MA; Phillips R; Hart A
Inflamm Bowel Dis; 2012 Oct; 18(10):1825-34. PubMed ID: 22223472
[TBL] [Abstract][Full Text] [Related]
8. Adalimumab for Crohn's disease: long-term sustained benefit in a population-based cohort of 438 patients.
Peters CP; Eshuis EJ; Toxopeüs FM; Hellemons ME; Jansen JM; D'Haens GR; Fockens P; Stokkers PC; Tuynman HA; van Bodegraven AA; Ponsioen CY;
J Crohns Colitis; 2014 Aug; 8(8):866-75. PubMed ID: 24491515
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of infliximab and adalimumab in Crohn's disease: a single centre study.
Zorzi F; Zuzzi S; Onali S; Calabrese E; Condino G; Petruzziello C; Ascolani M; Pallone F; Biancone L
Aliment Pharmacol Ther; 2012 Jun; 35(12):1397-407. PubMed ID: 22519466
[TBL] [Abstract][Full Text] [Related]
10. Exploring the use of adalimumab for patients with moderate Crohn's disease: subanalyses from induction and maintenance trials.
Sandborn WJ; Colombel JF; Panés J; Castillo M; Robinson AM; Zhou Q; Yang M; Thakkar R
J Crohns Colitis; 2013 Dec; 7(12):958-67. PubMed ID: 23517933
[TBL] [Abstract][Full Text] [Related]
11. Similar response to adalimumab in patients with active Crohn's disease either naive to biologic agents or with prior loss of response or intolerance to infliximab.
Triantafillidis JK; Mantzaris G; Karagiannis J; Papavasilliou E; Papatheodoridis G; Fouskas J; Malgarinos G; Gikas A; Papamichael K; Mathou N; Symboulakis E; Karamanolis D
Rev Med Chir Soc Med Nat Iasi; 2010; 114(1):85-90. PubMed ID: 20509281
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of adalimumab for the treatment of extraintestinal manifestations of Crohn's disease.
Barreiro-de-Acosta M; Lorenzo A; Domínguez-Muñoz JE
Rev Esp Enferm Dig; 2012 Sep; 104(9):468-72. PubMed ID: 23130854
[TBL] [Abstract][Full Text] [Related]
13. Adalimumab dose escalation is effective for managing secondary loss of response in Crohn's disease.
Ma C; Huang V; Fedorak DK; Kroeker KI; Dieleman LA; Halloran BP; Fedorak RN
Aliment Pharmacol Ther; 2014 Nov; 40(9):1044-55. PubMed ID: 25185992
[TBL] [Abstract][Full Text] [Related]
14. Fourteen-Year Anti-TNF Therapy in Crohn's Disease Patients: Clinical Characteristics and Predictive Factors.
Osamura A; Suzuki Y
Dig Dis Sci; 2018 Jan; 63(1):204-208. PubMed ID: 29209921
[TBL] [Abstract][Full Text] [Related]
15. Adalimumab produces clinical remission and reduces extraintestinal manifestations in Crohn's disease: results from CARE.
Löfberg R; Louis EV; Reinisch W; Robinson AM; Kron M; Camez A; Pollack PF
Inflamm Bowel Dis; 2012 Jan; 18(1):1-9. PubMed ID: 21351211
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of Adalimumab in Korean Patients with Crohn's Disease.
Sohn IW; Kim ST; Kim B; Lee HJ; Park SJ; Hong SP; Kim TI; Kim WH; Cheon JH
Gut Liver; 2016 Mar; 10(2):255-61. PubMed ID: 26470766
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of anti-TNFα drugs in patients with Crohn's disease who do not achieve remission with their first anti-TNFα agent.
R-Grau Mdel C; Chaparro M; Mesonero F; Barreiro-de Acosta M; Castro L; Castro M; Domènech E; Mancenido N; Pérez-Calle JL; Taxonera C; Barrio J; De Francisco R; Fernández-Salgado E; Luzón L; Merino O; Oltra L; Saro C; Bermejo F; García-Sánchez V; Ginard D; Gutiérrez A; Vera I; Antón R; Ber Y; Calvet X; Gisbert JP
Dig Liver Dis; 2016 Jun; 48(6):613-9. PubMed ID: 26992847
[TBL] [Abstract][Full Text] [Related]
18. Increased effectiveness of early therapy with anti-tumor necrosis factor-α vs an immunomodulator in children with Crohn's disease.
Walters TD; Kim MO; Denson LA; Griffiths AM; Dubinsky M; Markowitz J; Baldassano R; Crandall W; Rosh J; Pfefferkorn M; Otley A; Heyman MB; LeLeiko N; Baker S; Guthery SL; Evans J; Ziring D; Kellermayer R; Stephens M; Mack D; Oliva-Hemker M; Patel AS; Kirschner B; Moulton D; Cohen S; Kim S; Liu C; Essers J; Kugathasan S; Hyams JS;
Gastroenterology; 2014 Feb; 146(2):383-91. PubMed ID: 24162032
[TBL] [Abstract][Full Text] [Related]
19. Anti-TNF Therapy Within 2 Years of Crohn's Disease Diagnosis Improves Patient Outcomes: A Retrospective Cohort Study.
Ma C; Beilman CL; Huang VW; Fedorak DK; Kroeker KI; Dieleman LA; Halloran BP; Fedorak RN
Inflamm Bowel Dis; 2016 Apr; 22(4):870-9. PubMed ID: 26818419
[TBL] [Abstract][Full Text] [Related]
20. Adalimumab combined with ciprofloxacin is superior to adalimumab monotherapy in perianal fistula closure in Crohn's disease: a randomised, double-blind, placebo controlled trial (ADAFI).
Dewint P; Hansen BE; Verhey E; Oldenburg B; Hommes DW; Pierik M; Ponsioen CI; van Dullemen HM; Russel M; van Bodegraven AA; van der Woude CJ
Gut; 2014 Feb; 63(2):292-9. PubMed ID: 23525574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]